Bausch Health Companies Inc. (TSE:BHC – Get Rating) Senior Officer Robert Allen Spurr sold 1,595 shares of the stock in a transaction on Thursday, April 14th. The stock was sold at an average price of C$27.96, for a total value of C$44,595.24. Following the completion of the sale, the insider now directly owns 24,617 shares in the company, valued at C$688,276.55.
Robert Allen Spurr also recently made the following trade(s):
- On Tuesday, March 15th, Robert Allen Spurr sold 4,846 shares of Bausch Health Companies stock. The stock was sold at an average price of C$28.42, for a total value of C$137,703.94.
BHC stock traded down C$1.28 during trading on Monday, reaching C$26.71. The stock had a trading volume of 448,076 shares, compared to its average volume of 502,585. Bausch Health Companies Inc. has a 52 week low of C$26.44 and a 52 week high of C$42.45. The stock’s 50 day moving average is C$29.69 and its two-hundred day moving average is C$32.13. The company has a current ratio of 1.08, a quick ratio of 0.45 and a debt-to-equity ratio of 4,000.66. The firm has a market cap of C$9.61 billion and a PE ratio of -8.04.
About Bausch Health Companies (Get Rating)
Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.